# Can a Telehealth Brand Advertise Retatrutide?

Reviewed October 12, 2026 · By Michael Borgia, MedScale Health

## Short answer

As of October 2026, no. FDA says retatrutide cannot be used in compounding under federal law, is not a component of any FDA-approved drug and has not been found safe and effective for any condition, and it has warned telehealth companies for marketing it. LegitScript says certified businesses may not offer, promote or advertise it, and that content encouraging its use is impermissible even if the business doesn't sell it. MedScale Health, a paid ads agency for US telehealth brands and clinics, does not run retatrutide ads.

## What this means for you

- Retatrutide is an investigational drug still in clinical trials. FDA says it cannot be used in compounding and is not a component of any FDA-approved drug.
- FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers.
- For LegitScript-certified businesses, offering, promoting or advertising retatrutide is a violation, and so is content that encourages its use, whether or not the business sells it.
- Meta needs active LegitScript certification for prescription drug ads and TikTok needs proof of FDA approval, while Google's unapproved substances rules and Microsoft's ban on experimental treatments close the other routes.
- Waitlists, research-use sales and education pages that end in a call to action are not workarounds.

MedScale Health, a paid ads agency for US telehealth brands and clinics on Meta, Google, Microsoft and TikTok, gets asked about retatrutide by GLP-1 brands. This page sets out FDA's position, LegitScript's September 22, 2026 guidance, what each ad platform allows, and why an education funnel does not change the answer. This page is marketing guidance, not medical or legal advice. Platform policies and FDA positions change, so check the sources listed at the end before acting on a specific rule.

## FDA's position

As of October 2026, FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, is direct: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition." The same section says FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers, and warned ingredient distributors and outsourcing facilities that sold or repackaged it.

FDA has also warned companies that sold unapproved drugs containing retatrutide and other GLP-1s labeled "for research purposes" or "not for human consumption", which FDA says were sold directly to consumers for human use with dosing instructions. Our answer on research peptides versus prescribed peptides covers why that label changes nothing.

## Why it can't be compounded

LegitScript's post explains the mechanics. A 503A pharmacy generally needs a substance to be on the 503A Bulk Drug Substances List, the subject of a USP or National Formulary monograph, or a component of an FDA-approved drug. 503B outsourcing facilities can only compound substances on Category 1 of the 503B Bulks List. LegitScript says retatrutide and cagrilintide remain investigational drugs still in clinical trials, haven't gone through FDA's compounding advisory committee review at all, and meet none of these thresholds.

That puts retatrutide behind peptides such as BPC-157, which FDA's Pharmacy Compounding Advisory Committee has reviewed. Even there, LegitScript notes that an advisory recommendation doesn't authorize compounding or change the law; only a final rule changes a substance's status.

## LegitScript: offering, promoting and advertising all count

LegitScript's September 22, 2026 post, "The Peptide Boom: Why So Many Popular Products Are Still Off-Limits", says violations "aren't limited to actually dispensing or prescribing an impermissible peptide. They also include offering the product, promoting it, or advertising it." Partnering with a separate entity that dispenses or prescribes on the business's behalf "doesn't provide a workaround either", and businesses found in violation "will be subject to enforcement action."

That certificate is the key to a telehealth brand's prescription drug advertising: Meta requires active LegitScript certification, and Google allows US telemedicine providers accredited by LegitScript. A retatrutide ad puts the certificate behind every other ad at risk.

## Why education content is not a workaround

The common plan is to skip the product ad and publish education: a guide, a waitlist, an explainer video with a booking link. Under LegitScript's Transparency Standard, content that could reasonably be considered promotional, meaning it encourages the use of an unapproved drug, is impermissible "regardless of whether the business actually offers the product." The signals it lists include:

- Claims about efficacy or safety, particularly compared to FDA-approved medications.
- Dosing recommendations for an unapproved drug.
- Specific treatment benefits, or calling a substance clinically proven or scientifically backed without clear disclosures about the limits of the research.
- Implying the substance is FDA-approved or legally permitted for compounding.
- A call to action inviting readers to ask about obtaining or using the product, unless the content clearly discloses that it is not approved and not available for sale or prescription.

LegitScript's test is whether content mainly helps a reader understand a substance and the evidence, or gives the reader a reason to want, seek out or use it. A paid ad is bought to do the second. Meta's Drugs and Pharmaceuticals policy allows references to prohibited drugs for news and awareness only as long as they don't promote the sale or consumption of those substances, and a retatrutide waitlist ad is built to create demand for a drug FDA says cannot be compounded.

## What each platform says

- Meta: prescription drug ads need active LegitScript certification and Meta's authorization, and Meta bars ads that encourage the consumption of potentially unsafe drugs, as Meta determines.
- Google: its Unapproved substances policy bans promoting products that have been subject to any government or regulatory action or warning, and non-government-approved products marketed as safe or effective for treating a condition. Google also doesn't allow the promotion of speculative or experimental medical treatments.
- Microsoft: its Healthcare and Pharmaceutical policy does not accept ads for clinical trials, experimental treatments or medical research solicitations, and bars statements that misrepresent a product's regulatory approval.
- TikTok: prescription medicine ads in the US need proof of approval and certification from regulators such as the FDA. Retatrutide has no FDA approval to show.

## What to run instead

- Advertise what is approved. Foundayo, the Wegovy pill and the approved injectables can be advertised through the certified routes.
- Add retatrutide as a negative keyword on Google so broad match doesn't serve your ads on those searches, and keep the name out of ad copy, creator briefs and landing pages.
- If you publish news about retatrutide, report the development and its status and keep it away from any call to action. LegitScript says purely factual reporting of a regulatory update generally doesn't need its disclaimers, as long as it sticks to the development itself.
- Watch FDA, not the feed. If FDA approves a retatrutide product, the approved-drug rules apply. Until then the answer is no.

## What MedScale does

MedScale Health doesn't run retatrutide ads, waitlists or lead magnets, and checks a GLP-1 brand's pages, creator content and keyword lists for the name before launch. The plan is built around what the brand can prescribe and advertise today. Start with a growth audit at medscale.health/audit.

## Next step

**Check your ad before Meta does.** Paste your ad copy into the free pre-check. It flags the lines a reviewer reads as personal attributes, outcome promises or drug claims.

- [Run the free pre-check](https://medscale.health/pre-check)
- [Already restricted? Start a rescue](https://medscale.health/rescue)
- [Telehealth marketing agency](https://medscale.health/telehealth)
- [Get a free Growth Audit](https://medscale.health/audit): a written read of your ads, pages and eligibility, with a plan

## FAQ

**Can a compounding pharmacy make retatrutide?**

No. FDA says retatrutide cannot be used in compounding under federal law, is not a component of any FDA-approved drug, and has not been found safe and effective for any condition. LegitScript adds that it meets none of the thresholds for 503A or 503B compounding.

**Can we run a retatrutide waitlist to capture demand?**

LegitScript lists a call to action inviting readers to ask about obtaining or using an unapproved product as a sign of promotional content, impermissible for certified businesses whether or not they sell it. A waitlist ad is that call to action.

**Is an educational blog post about retatrutide allowed?**

LegitScript says factual reporting of a regulatory update generally is, if it sticks to the development. Efficacy claims, dosing, benefit claims or a booking link turn it into promotion, and buying ads to push the post makes it harder to call education.

**What about selling retatrutide as a research peptide?**

FDA has warned companies selling unapproved drugs, including retatrutide, labeled for research purposes or not for human consumption, which it says were sold to consumers for human use with dosing instructions. The label is not a route to advertising.

## Sources

- [FDA (current as of Oct 1, 2026): FDA's concerns with unapproved GLP-1 drugs used for weight loss](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) (checked October 12, 2026)
- [LegitScript (Sep 22, 2026): The Peptide Boom, why so many popular products are still off-limits](https://www.legitscript.com/healthcare/the-peptide-boom-why-so-many-popular-products-are-still-off-limits/) (checked October 12, 2026)
- [Meta Advertising Standards: Drugs and Pharmaceuticals](https://transparency.meta.com/policies/ad-standards/restricted-goods-services/drugs-pharmaceuticals/) (checked October 12, 2026)
- [Google Ads policy: Unapproved substances](https://support.google.com/adspolicy/answer/15595718?hl=en) (checked October 12, 2026)
- [Google Ads policy: Healthcare and medicines (United States section)](https://support.google.com/adspolicy/answer/176031?hl=en) (checked October 12, 2026)
- [Google Ads policy: Prescription drug services](https://support.google.com/adspolicy/answer/15598647?hl=en) (checked October 12, 2026)
- [Microsoft Advertising: Healthcare and Pharmaceutical policy (last updated Oct 5, 2026)](https://help.ads.microsoft.com/#apex/ads/en/60379/-1) (checked October 12, 2026)
- [TikTok Advertising Policies: Healthcare and Pharmaceuticals (last updated September 2026, United States section)](https://ads.tiktok.com/help/article/tiktok-ads-policy-healthcare-pharmaceuticals) (checked October 12, 2026)

## Related

- [Research Peptides vs Prescribed Peptides: Which Carries More Advertising Risk?](https://medscale.health/answers/research-peptides-vs-prescribed-peptides)
- [Can You Advertise BPC-157, and What Does the FDA Status Mean?](https://medscale.health/answers/bpc-157-fda-bulk-substances-list)
- [Can You Advertise Peptides on Meta?](https://medscale.health/answers/can-you-advertise-peptides-on-meta)
- [Can You Advertise Foundayo and the Wegovy Pill? Ad Rules for GLP-1 Pills on Meta, Google, TikTok and Microsoft](https://medscale.health/answers/can-you-advertise-foundayo-and-the-wegovy-pill)

Canonical page: https://medscale.health/answers/can-you-advertise-retatrutide